ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Variants on Inpatient Clinical Outcome.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review.Human vaccines & immunotherapeutics · 2023Pooled it
- Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: a systematic review and metanalysis.BMJ global health · 2023Pooled it
- Review
- Characteristics and predictors of severe outcomes of COVID-19 cases presenting to the emergency department of a major Australian referral hospital: A record linkage study.Emergency medicine Australasia : EMA · 2025Article
- Article
- Elevated non-invasive liver fibrosis scores at admission are independent risk factors for severe COVID-19: a retrospective cohort study from 2020 to 2024.Frontiers in medicine · 2025Article
- A Prospective Study of Immune Response After COVID-19 or Vaccination and Correlation Between Avidity Index and Neutralizing Capacity.Advances in virology · 2025Article
- Application of machine learning algorithms to identify serological predictors of COVID-19 severity and outcomes.Communications medicine · 2024Article
- Dysregulated platelet function in patients with postacute sequelae of COVID-19.Vascular medicine (London, England) · 2024Article
- Cost-Effectiveness of Universal Asymptomatic Preoperative SARS-CoV-2 Polymerase Chain Reaction Screening: A Cost-Utility Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- High productionHeliyon · 2024Article
- COVID-19 waves in an urban setting 2020-2022: an electronic medical record analysis.Frontiers in public health · 2024Article
- Article
- Application of machine learning models to identify serological predictors of COVID-19 severity and outcomes.Research square · 2023Article
- Assessment of clinical characteristics and viral load in individuals infected by Delta and Omicron variants of SARS-CoV-2.Heliyon · 2023Article
- Article
- Editorial: COVID-19: From bedside to follow-up.Frontiers in medicine · 2023Article
- Healthcare Workers' Knowledge and Perception of the SARS-CoV-2 Omicron Variant: A Multinational Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2022Article
Corrections and comments
- Update of
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPrior observation has shown differences in COVID-19 hospitalization risk between SARS-CoV-2 variants, but limited information describes hospitalization outcomes.
methodsInpatients with COVID-19 at 5 hospitals in the eastern United States were included if they had hypoxia, tachypnea, tachycardia, or fever, and SARS-CoV-2 variant data, determined from whole-genome sequencing or local surveillance inference. Analyses were stratified by history of SARS-CoV-2 vaccination or infection. The average effect of SARS-CoV-2 variant on 28-day risk of severe disease, defined by advanced respiratory support needs, or death was evaluated using models weighted on propensity scores derived from baseline clinical features.
resultsSevere disease or death within 28 days occurred for 977 (29%) of 3369 unvaccinated patients and 269 (22%) of 1230 patients with history of vaccination or prior SARS-CoV-2 infection. Among unvaccinated patients, the relative risk of severe disease or death for Delta variant compared with ancestral lineages was 1.30 (95% confidence interval [CI]: 1.11-1.49). Compared with Delta, the risk for Omicron patients was .72 (95% CI: .59-.88) and compared with ancestral lineages was .94 (.78-1.1). Among Omicron and Delta infections, patients with history of vaccination or prior SARS-CoV-2 infection had half the risk of severe disease or death (adjusted hazard ratio: .40; 95% CI: .30-.54), but no significant outcome difference by variant.
conclusionsAlthough risk of severe disease or death for unvaccinated inpatients with Omicron was lower than with Delta, it was similar to ancestral lineages. Severe outcomes were less common in vaccinated inpatients, with no difference between Delta and Omicron infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.